Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YM150 in Healthy Caucasian and Japanese Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Darexaban (Primary)
- Indications Acute coronary syndromes; Thromboembolism; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
- 10 Mar 2011 New trial record